CA2163539A1 - N-morpholino-n-nitrosaminoacetonitrile cyclodextrin inclusion complexes - Google Patents
N-morpholino-n-nitrosaminoacetonitrile cyclodextrin inclusion complexesInfo
- Publication number
- CA2163539A1 CA2163539A1 CA002163539A CA2163539A CA2163539A1 CA 2163539 A1 CA2163539 A1 CA 2163539A1 CA 002163539 A CA002163539 A CA 002163539A CA 2163539 A CA2163539 A CA 2163539A CA 2163539 A1 CA2163539 A1 CA 2163539A1
- Authority
- CA
- Canada
- Prior art keywords
- complexes
- sin
- inclusion complexes
- ions
- cyclodextrins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 3
- 150000002500 ions Chemical class 0.000 abstract 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 2
- 229940097362 cyclodextrins Drugs 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 abstract 1
- 239000012736 aqueous medium Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000003054 catalyst Substances 0.000 abstract 1
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
Abstract
New inclusion complexes which are stable in their solid state formed of SIN-1A and cyclodextrins or cyclodextrin derivatives, and optionally also containing ions as catalyst or stabilizer. The complexes release nitric oxide at room temperature upon dissolving in water or aqueous systems. Pharmaceutical compositions as well as kits containing the complexes. The kits are to be used as NO-liberating standards to release NO in a predictable amount and rate on dissolving in aqueous media. Processes for the preparation of the complexes by subjecting at a suitable pH SIN-1 to the catalytic action of ions to shift the equilibrium towards formation of SIN-IA in the presence of cyclodextrins or cyclodextrin derivatives capable of forming inclusion complexes, whereby the SIN-1A formed is immediately complexed and stabilized and isolating in the solid state the obtained new complexes optionally containing ions.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP9401183 | 1994-04-26 | ||
| HU9401183A HU218280B (en) | 1994-04-26 | 1994-04-26 | Cyclodextrin inclusion complexes containing sin-1a which are stable intheir solid state, process for their preparation and pharmaceutical compositions containing the comlexes |
| PCT/HU1995/000011 WO1995029172A1 (en) | 1994-04-26 | 1995-04-25 | N-morpholino-n-nitrosaminoacetonitril cyclodextrin inclusion complexes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2163539A1 true CA2163539A1 (en) | 1995-11-02 |
| CA2163539C CA2163539C (en) | 2003-04-01 |
Family
ID=10985114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002163539A Expired - Lifetime CA2163539C (en) | 1994-04-26 | 1995-04-25 | N-morpholino-n-nitrosaminoacetonitrile cyclodextrin inclusion complexes |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US5698535A (en) |
| EP (1) | EP0705255B1 (en) |
| JP (1) | JP3434828B2 (en) |
| KR (1) | KR960703404A (en) |
| CN (1) | CN1060164C (en) |
| AT (1) | ATE197708T1 (en) |
| AU (1) | AU694219B2 (en) |
| BG (1) | BG61974B1 (en) |
| BR (1) | BR9506155A (en) |
| CA (1) | CA2163539C (en) |
| CZ (1) | CZ316395A3 (en) |
| DE (1) | DE69519463T2 (en) |
| DK (1) | DK0705255T3 (en) |
| ES (1) | ES2153897T3 (en) |
| FI (1) | FI956156A0 (en) |
| GR (1) | GR3035356T3 (en) |
| HR (1) | HRP950249A2 (en) |
| HU (1) | HU218280B (en) |
| IL (1) | IL113491A (en) |
| LT (1) | LT4167B (en) |
| LV (1) | LV11543B (en) |
| MD (1) | MD1419G2 (en) |
| NO (1) | NO311030B1 (en) |
| NZ (1) | NZ285149A (en) |
| PL (1) | PL312183A1 (en) |
| PT (1) | PT705255E (en) |
| RO (1) | RO114449B1 (en) |
| RU (1) | RU2136698C1 (en) |
| SI (1) | SI0705255T1 (en) |
| SK (1) | SK155195A3 (en) |
| WO (1) | WO1995029172A1 (en) |
| YU (1) | YU25995A (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
| DE60032388T2 (en) * | 1999-11-12 | 2008-01-10 | Frères Roquette | CRYSTALLINE MIXTURES OF PARTIAL METHYLETHERS OF BETA CYCLODEXTRIN AND RELATED COMPOUNDS |
| FR2805462B1 (en) * | 2000-02-24 | 2003-08-15 | Therabel Res | NEW ORAL GALENIC FORM WITH EXTENDED RELEASE OF MOLSIDOMINE |
| TWI321054B (en) | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
| EP1219306A1 (en) | 2000-12-29 | 2002-07-03 | Nicox S.A. | Compositions comprising cyclodextrins and NO- releasing drugs |
| CA2497792C (en) | 2002-09-06 | 2014-08-05 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| CN1717209A (en) * | 2002-10-09 | 2006-01-04 | 植入疗法公司 | Cyclodextrin-based materials, compositions and uses related thereto |
| US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| JP6220126B2 (en) * | 2009-11-23 | 2017-10-25 | セルリアン・ファーマ・インコーポレイテッド | Polymers based on cyclodextrins for therapeutic delivery |
| US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
| CA3078625C (en) | 2017-10-09 | 2023-01-17 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
| WO2020185909A2 (en) | 2019-03-14 | 2020-09-17 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
| CN116249522A (en) * | 2020-07-20 | 2023-06-09 | 深圳迈瑞生物医疗电子股份有限公司 | Application of composition in platelet depolymerization, depolymerization reagent and depolymerization method |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5039705A (en) * | 1989-09-15 | 1991-08-13 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof |
| US5208233A (en) * | 1989-09-15 | 1993-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof |
| US5212204A (en) * | 1989-10-18 | 1993-05-18 | The United States Of America As Represented By The Department Of Health And Human Services | Antihypertensive compositions and use thereof |
| HU211648A9 (en) * | 1990-03-28 | 1995-12-28 | Chinoin Gyogyszer Es Vegyeszet | Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same |
| CA2119572C (en) * | 1991-09-24 | 2005-07-05 | Larry Kay Keefer | Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs |
| US5389675A (en) * | 1992-03-27 | 1995-02-14 | The United States Of America As Represented By The Department Of Health And Human Services | Mixed ligand metal complexes of nitric oxide-nucleophile adducts useful as cardiovascular agents |
-
1994
- 1994-04-26 HU HU9401183A patent/HU218280B/en not_active IP Right Cessation
-
1995
- 1995-04-25 AT AT95918104T patent/ATE197708T1/en active
- 1995-04-25 IL IL11349195A patent/IL113491A/en not_active IP Right Cessation
- 1995-04-25 HR HRP9401183A patent/HRP950249A2/en not_active Application Discontinuation
- 1995-04-25 KR KR1019950705912A patent/KR960703404A/en not_active Application Discontinuation
- 1995-04-25 SK SK1551-95A patent/SK155195A3/en unknown
- 1995-04-25 JP JP52720795A patent/JP3434828B2/en not_active Expired - Lifetime
- 1995-04-25 BR BR9506155A patent/BR9506155A/en not_active Application Discontinuation
- 1995-04-25 SI SI9530435T patent/SI0705255T1/en unknown
- 1995-04-25 DK DK95918104T patent/DK0705255T3/en active
- 1995-04-25 CZ CZ953163A patent/CZ316395A3/en unknown
- 1995-04-25 ES ES95918104T patent/ES2153897T3/en not_active Expired - Lifetime
- 1995-04-25 WO PCT/HU1995/000011 patent/WO1995029172A1/en not_active Application Discontinuation
- 1995-04-25 RU RU96100760A patent/RU2136698C1/en active
- 1995-04-25 CN CN95190353A patent/CN1060164C/en not_active Expired - Fee Related
- 1995-04-25 US US08/571,853 patent/US5698535A/en not_active Expired - Fee Related
- 1995-04-25 RO RO95-02248A patent/RO114449B1/en unknown
- 1995-04-25 PL PL95312183A patent/PL312183A1/en unknown
- 1995-04-25 PT PT95918104T patent/PT705255E/en unknown
- 1995-04-25 YU YU25995A patent/YU25995A/en unknown
- 1995-04-25 MD MD95-0440A patent/MD1419G2/en unknown
- 1995-04-25 EP EP95918104A patent/EP0705255B1/en not_active Expired - Lifetime
- 1995-04-25 DE DE69519463T patent/DE69519463T2/en not_active Expired - Lifetime
- 1995-04-25 NZ NZ285149A patent/NZ285149A/en unknown
- 1995-04-25 AU AU24159/95A patent/AU694219B2/en not_active Expired
- 1995-04-25 CA CA002163539A patent/CA2163539C/en not_active Expired - Lifetime
- 1995-12-20 FI FI956156A patent/FI956156A0/en not_active Application Discontinuation
- 1995-12-22 NO NO19955283A patent/NO311030B1/en not_active IP Right Cessation
- 1995-12-22 LT LT95-133A patent/LT4167B/en not_active IP Right Cessation
- 1995-12-22 LV LVP-95-383A patent/LV11543B/en unknown
-
1996
- 1996-01-26 BG BG100313A patent/BG61974B1/en unknown
-
2001
- 2001-02-02 GR GR20010400181T patent/GR3035356T3/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2163539A1 (en) | N-morpholino-n-nitrosaminoacetonitrile cyclodextrin inclusion complexes | |
| AU4161399A (en) | Nucleation and growth of magnetic metal oxide nanoparticles and its use | |
| CA2120519A1 (en) | Hardness suppression in urea solutions | |
| TW328549B (en) | Improved PVOH-based coating solutions | |
| CA2205305A1 (en) | Stable budesonide solutions, method of preparing them and use of these solutions as enema preparations and pharmaceutical foams | |
| IL130892A0 (en) | A method of manufacturing a solid state capacitor | |
| CA2018230A1 (en) | Aqueous folinate solution - stable at refrigerator temperature, as well as process for its preparation | |
| JPS6240995B2 (en) | ||
| EP0941999A3 (en) | Preparation of azithromycin dihydrate | |
| KR970026910A (en) | Method for preparing hydroxylammonium salt | |
| CA2388325A1 (en) | Ciclesonide-containing aqueous pharmaceutical composition | |
| JPS5639782A (en) | Stabilization of thrombin | |
| CA2023114A1 (en) | Microorganism for selective production of a specific component of avermectin and a method for selective production thereof | |
| EP0274444A3 (en) | Solution inbuprofen complexes, compositions and processes for preparing the same | |
| IE45024L (en) | Estradiol-17-dihydrogen phosphates | |
| KR890017265A (en) | Divalent manganese ion [Mn (II)] containing composition and its manufacturing method | |
| JP2798514B2 (en) | Inclusion compound of γ-cyclodextrin and method for separation and purification of γ-cyclodextrin | |
| JPS5233662A (en) | Preparation of n2-naphthalenesulfonyl-alginamides and acid addition sa lts thereof | |
| JPS645553A (en) | Deodorizing composition | |
| KR930001932A (en) | Manufacturing method of purifier and deodorant | |
| JPS55108887A (en) | Novel oligo saccharide and its preparation | |
| UA7475A (en) | Process for the preparation of iodosulfon | |
| UA10967C2 (en) | 4.5-dimethyl-2-H-propylthio-2-W-H-perfluorbutyl-3H,6H-thiaine 4.5-DIMETHYL-2-H-PROPYLATHIO-2-W-H-PERFLUORBUTYL-3H. 6H-THIAINE AND A PROCESS FOR ITS PREPARATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20150427 |